Real-life follow-up after discontinuation of anti-PD1 therapy for complete-response cutaneous squamous cell carcinoma in patients over 75 years of age

Anti-PD1 therapy is effective and safe in elderly patients. CR can be achieved quickly and maintained, despite early treatment discontinuation. The use of anti-PD1 therapy is therefore encouraged even in this fragile and comorbid population, with discontinuation planned as soon as a complete response is obtained to limit the duration of treatment and promote quality of life for patients. Further studies and prolonged follow-up are needed to establish guidelines regarding anti-PD1 discontinuation.